# First authorships

**Al-Mashhadi, Z.** K., Viggers, R., Fuglsang-Nielsen, R., Vestergaard, P., Gregersen, S., & Starup-Linde, J. (2022). *The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors: A danish nationwide cohort study*. *Frontiers in Endocrinology*, *13*. <https://doi.org/10.3389/fendo.2022.882998>

**Al-Mashhadi, Z.** K., Viggers, R., Starup-Linde, J., Vestergaard, P., & Gregersen, S. (2022). *SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: A nationwide cohort study*. *Frontiers in Endocrinology*, *13*. <https://doi.org/10.3389/fendo.2022.861422>

**Al-Mashhadi, Z.**, Viggers, R., Fuglsang-Nielsen, R., Langdahl, B., Vestergaard, P., Gregersen, S., & Starup-Linde, J. (2020). *Bone health in the elderly with type 2 diabetes mellitus–a systematic review*. *OBM Geriatrics*, *4*(2), 1–65. <https://doi.org/10.21926/obm.geriatr.2002123>

**Al-Mashhadi, Z.**, Viggers, R., Fuglsang-Nielsen, R., Vries, F. de, Bergh, J. P. van den, Harsløf, T., Langdahl, B., Gregersen, S., & Starup-Linde, J. (2020). *Glucose-lowering drugs and fracture risk—a systematic review*. *Current Osteoporosis Reports*, *18*(6), 737–758. <https://doi.org/10.1007/s11914-020-00638-8>

# Co-authorships

Mellbye, F. D., Nguyen, M. D., Hermansen, K., Jeppesen, P. B., **Al-Mashhadi, Z.** K., Ringgaard, S., & Gregersen, S. (2024). *Effects of 12-week supplementation with coffee diterpene cafestol in healthy subjects with increased waist circumference: A randomized, placebo-controlled trial*. *Nutrients*, *16*(19), 3232. <https://doi.org/10.3390/nu16193232>

Starup-Linde, J., Westberg-Rasmussen, S., Viggers, R., **Al-Mashhadi, Z.** K., Handberg, A., Vestergaard, P., & Gregersen, S. (2024). *Serum osteoglycin is stable during various glycemic challenges in healthy men*. *Endocrine*, *85*(3), 1117–1121. <https://doi.org/10.1007/s12020-024-03789-1>

Hulten, V. van, Driessen, J. H. M., Starup-Linde, J. K., **Al-Mashhadi, Z.** K., Viggers, R., Klungel, O. H., Souverein, P. C., Vestergaard, P., Stehouwer, C. D. A., & Bergh, J. P. van den. (2023). *The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus*. *Diabetes, Obesity and Metabolism*, *25*(11), 3235–3247. <https://doi.org/10.1111/dom.15220>

Viggers, R., **Al-Mashhadi, Z.**, Starup-Linde, J., & Vestergaard, P. (2022). *The efficacy of alendronate versus denosumab on major osteoporotic fracture risk in elderly patients with diabetes mellitus: A danish retrospective cohort study*. *Frontiers in Endocrinology*, *12*. <https://doi.org/10.3389/fendo.2021.826997>

Al-Mashhadi, R. H., Al-Mashhadi, A. L., Nasr, Z. P., Mortensen, M. B., Lewis, E. A., Camafeita, E., Ravlo, K., **Al-Mashhadi, Z.**, Kjær, D. W., Palmfeldt, J., Bie, P., Jensen, J. M., Nørgaard, B. L., Falk, E., Vázquez, J., & Bentzon, J. F. (2021). *Local pressure drives low-density lipoprotein accumulation and coronary atherosclerosis in hypertensive minipigs*. *Journal of the American College of Cardiology*, *77*(5), 575–589. <https://doi.org/10.1016/j.jacc.2020.11.059>

Viggers, R., **Al-Mashhadi, Z.**, Starup-Linde, J., & Vestergaard, P. (2021). *Alendronate use and risk of type 2 diabetes: A nationwide danish nested case-control study*. *Frontiers in Endocrinology*, *12*. <https://doi.org/10.3389/fendo.2021.771426>

Viggers, R., **Al-Mashhadi, Z.**, Fuglsang-Nielsen, R., Gregersen, S., & Starup-Linde, J. (2020). *The impact of exercise on bone health in type 2 diabetes mellitus—a systematic review*. *Current Osteoporosis Reports*, *18*(4), 357–370. <https://doi.org/10.1007/s11914-020-00597-0>

Al-Mashhadi, R. H., Tolbod, L. P., Bloch, L. Ø., Bjørklund, M. M., Nasr, Z. P., **Al-Mashhadi, Z.**, Winterdahl, M., Frøkiær, J., Falk, E., & Bentzon, J. F. (2019). *18Fluorodeoxyglucose accumulation in arterial tissues determined by PET signal analysis*. *Journal of the American College of Cardiology*, *74*(9), 1220–1232. <https://doi.org/10.1016/j.jacc.2019.06.057>

# Conference abstracts

**Al-Mashhadi, Z.** K., Viggers, R., Fuglsang-Nielsen, R., Vestergaard, P., Gregersen, S., & Starup-Linde, J. (2022). *Fracture risk in treatment with GLP-1RA compared to DPP-4i: A Danish nationwide cohort study*. *Diabetologia*, *65, suppl. 1, Abstract no. 351*, S183.

**Al-Mashhadi, Z.** K., Viggers, R., Starup-Linde, J., Vestergaard, P., & Gregersen, S. (2022). *SGLT2 inhibitor treatment does not increase risk of osteoporotic fractures compared to GLP-1 receptor agonists: A danish population-based cohort study*. *Endocrine Abstracts*. <https://doi.org/10.1530/endoabs.81.oc8.2>

# Works in progress

**Al-Mashhadi, Z.** K., Viggers, R., Starup-Linde, J., Langdahl, B. L., van Hulten, V., van den Bergh, J. P., Driessen, J., Vestergaard, P., & Gregersen, S. (n.d.). *Systemic glucocorticoid use increases fracture risk equally in those with and without type 2 diabetes mellitus: A Danish nationwide cohort study* [Work in Progress].